drugset / Trial / NCT00616460

ACRIPAB- Trial: Anti Coagulation Regimen In High Risk PAtients for Bleeding

NCT00616460

Phase 3 Completed 100 enrolled HaEmek Medical Center, Israel
RandomizedParallel-groupDouble-blindTreatment

Summary

To determine the safety/efficacy of Bivallirudin Vs unfractionated heparin (UFH) on top of dual antiplatelet therapy in patients with high tendency for bleeding during urgent and elective PCI.

Timeline

Start
2008-02
Primary completion
2011-10
Completion
2011-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Bivalirudin Peptide 1.75 mg/kg

Indications